Skip to main content
OpenTrials

Clinical trial condition

Pancreatic Ductal Adenocarcinoma

Explore clinical trials studying Pancreatic Ductal Adenocarcinoma. Study availability and eligibility vary by location and protocol.

181 public trials 74 recruiting studies
Refine in advanced search Browse all conditions

Pancreatic Ductal Adenocarcinoma trial results

Recruiting

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05851924

Conditions
Pancreatic Ductal Adenocarcinoma
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06673017

Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +9 more
Locations
  • Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Northwell Health Zuckerberg Cancer Center Lake Success, New York, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Recruiting

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Carolina BioOncology Institute Huntersville, North Carolina, United States
  • Sarah Cannon Research Institute University of Oklahoma Oklahoma City, Oklahoma, United States
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions